Tesetaxel
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| (2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10-[(dimethylamino)methyl]-4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methano[1,3]dioxolo[3,4]cyclodeca[1,2-d][1]benzoxet-3-yl benzoate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 333754-36-2 |
| ATC code | None |
| PubChem | CID 6918574 |
| UNII | UG97LO5M8Y |
| Chemical data | |
| Formula | C46H60FN3O13 |
| Mol. mass | 881.98 g/mol |
|
|
|
|
| |
|
Tesetaxel (DJ-927) is a drug being investigated for chemotherapy of various types of cancer, including breast cancer,[1] gastric cancer,[2] and other solid tumours.[3]
References [edit]
- ^ ClinicalTrials.gov NCT01609127 Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
- ^ ClinicalTrials.gov NCT01348009 Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
- ^ Saif, M. W.; Sarantopoulos, J.; Patnaik, A.; Tolcher, A. W.; Takimoto, C.; Beeram, M. (2011). "Tesetaxel, a new oral taxane, in combination with capecitabine: A phase I, dose-escalation study in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology 68 (6): 1565–1573. doi:10.1007/s00280-011-1639-3. PMID 21547572.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |